PANews reported on October 17th that YZi Labs announced the official launch of the second season of its EASY Residency, targeting Web3, AI, and Biotech entrepreneurs. The program has launched in four cities. Projects this season will focus on stablecoins/payments and DeFi, Web3 marketing and creator tools, agentic AI and data infrastructure, and gene therapy. Applications are open for the eight-week program.PANews reported on October 17th that YZi Labs announced the official launch of the second season of its EASY Residency, targeting Web3, AI, and Biotech entrepreneurs. The program has launched in four cities. Projects this season will focus on stablecoins/payments and DeFi, Web3 marketing and creator tools, agentic AI and data infrastructure, and gene therapy. Applications are open for the eight-week program.

YZi Labs: EASY Residency Season 2 Launches Globally, Focusing on Web3, AI, and Biotech

2025/10/17 17:19
1 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

PANews reported on October 17th that YZi Labs announced the official launch of the second season of its EASY Residency, targeting Web3, AI, and Biotech entrepreneurs. The program has launched in four cities. Projects this season will focus on stablecoins/payments and DeFi, Web3 marketing and creator tools, agentic AI and data infrastructure, and gene therapy. Applications are open for the eight-week program.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.